Anti-Inflammatory Peptide Nanoparticles Target Inflamed Gut Tissue to Treat Colitis in Mice

KPV-FK506 co-assembled nanoparticles targeted PepT1 on inflamed gut epithelium and outperformed either component alone in reducing inflammation, immune cell infiltration, and restoring tight junction proteins in both acute and chronic colitis models.

Mouse study using DSS-induced acute (2.5% DSS) and chronic (4% DSS) colitis models. Compared nanoparticles (NPs), KPV peptide alone, FK506 alone, DSS control, and saline control. Assessed body weight, colon length, disease activity, inflammatory cytokines, oxidative stress markers, immune cell infiltration, and tight junction protein expression.

IBD affects millions worldwide with limited treatment options. A peptide-based nanodrug that targets inflamed tissue directly could deliver more effective treatment with fewer systemic side effects than current oral or IV immunosuppressants.

Peptide-based nanomedicine is an emerging approach that combines the therapeutic properties of bioactive peptides with the targeting capabilities of nanotechnology. This study demonstrates that peptides can serve dual roles — both as the active drug and as part of the delivery vehicle — potentially simplifying drug design while improving targeted delivery to diseased tissue.

Mouse colitis model does not perfectly replicate human IBD. PepT1 expression patterns may differ in humans. Long-term safety, stability, and scalability of carrier-free nanoparticles are unknown. No comparison with current standard-of-care IBD treatments like biologics.